@article{39ebe495cd5e433ebe8e9a7c6375dc51,
title = "DNA-Based Nanocarriers to Enhance the Optoacoustic Contrast of Tumors In Vivo",
abstract = "Optoacoustic tomography (OT) enables non-invasive deep tissue imaging of optical contrast at high spatio-temporal resolution. The applications of OT in cancer imaging often rely on the use of molecular imaging contrast agents based on near-infrared (NIR) dyes to enhance contrast at the tumor site. While these agents afford excellent biocompatibility and minimal toxicity, they present limited optoacoustic signal generation capability and rapid renal clearance, which can impede their tumor imaging efficacy. In this work, a synthetic strategy to overcome these limitations utilizing biodegradable DNA-based nanocarrier (DNA-NC) platforms is introduced. DNA-NCs enable the incorporation of NIR dyes (in this case, IRDye 800CW) at precise positions to enable fluorescence quenching and maximize optoacoustic signal generation. Furthermore, these DNA-NCs show a prolonged blood circulation compared to the native fluorophores, facilitating tumor accumulation by the enhanced permeability and retention (EPR) effect. In vivo imaging of tumor xenografts in mice following intravenous administration of DNA-NCs reveals enhanced OT signals at 24 h when compared to free fluorophores, indicating promise for this method to enhance the optoacoustic signal generation capability and tumor uptake of clinically relevant NIR dyes.",
keywords = "cancer imaging, contrast agents, DNA nanotechnology, optical imaging, optoacoustics",
author = "James Joseph and Baumann, {Kevin N.} and Alejandro Postigo and Laura Bollepalli and Bohndiek, {Sarah E.} and Silvia Hern{\'a}ndez-Ainsa",
note = "Funding Information: J.J. and K.N.B. contributed equally to this work. This work was funded by a Cancer Research UK Cambridge Centre Pump Prime Research Grant (KAZA/071 and KNZA-151). K.N.B. acknowledges funding by ERASMUS + and a PROMOS scholarship awarded by the DAAD. J.J. and S.E.B. are funded by the EPSRC-CRUK Cancer Imaging Centre in Cambridge and Manchester (C197/A16465); CRUK (C14303/A17197, C47594/A16267, C9545/A29580) and the EU-FP7-agreement FP7- PEOPLE-2013-CIG-630729. S.H.A. acknowledges funding by the University of Zaragoza (UZ2018-CIE-04) and by Fundaci?n Ibercaja y Universidad de Zaragoza (JIUZ-2018-CIE-04). S.H.A. and A.P. acknowledge funding by the Gobierno de Arag?n-FSE (E47_20R). Funding Information: J.J. and K.N.B. contributed equally to this work. This work was funded by a Cancer Research UK Cambridge Centre Pump Prime Research Grant (KAZA/071 and KNZA‐151). K.N.B. acknowledges funding by ERASMUS + and a PROMOS scholarship awarded by the DAAD. J.J. and S.E.B. are funded by the EPSRC‐CRUK Cancer Imaging Centre in Cambridge and Manchester (C197/A16465); CRUK (C14303/A17197, C47594/A16267, C9545/A29580) and the EU‐FP7‐agreement FP7‐ PEOPLE‐2013‐CIG‐630729. S.H.A. acknowledges funding by the University of Zaragoza (UZ2018‐CIE‐04) and by Fundaci{\'o}n Ibercaja y Universidad de Zaragoza (JIUZ‐2018‐CIE‐04). S.H.A. and A.P. acknowledge funding by the Gobierno de Arag{\'o}n‐FSE (E47_20R). Publisher Copyright: {\textcopyright} 2020 Wiley-VCH GmbH",
year = "2021",
month = jan,
day = "20",
doi = "10.1002/adhm.202001739",
language = "English",
volume = "10",
journal = "Advanced Healthcare Materials",
issn = "2192-2640",
publisher = "Wiley",
number = "2",
}